EyePoint (EYPT) Total Liabilities (2011 - 2026)
EyePoint (EYPT) posted Total Liabilities of $57.7 million for Q1 2026, little changed sequentially from $57.9 million in Q4 2025, and down 10.01% YoY from $64.2 million in Q1 2025.
EyePoint (EYPT) Total Liabilities (2011 - 2026) Analysis & Trends
EyePoint has reported Total Liabilities for 16 years, with the latest figure at $57.7 million in Q1 2026.
- Quarterly Total Liabilities fell 10.01% year-over-year to $57.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.7 million (down 10.01% YoY) and the FY2025 annual result came in at $57.9 million, down 29.38% from the prior year.
- Total Liabilities steadied at $57.7 million in Q1 2026 per EYPT's latest filing, from $57.9 million in the prior quarter.
- Over five years, Total Liabilities peaked at $118.4 million in Q2 2023 and troughed at $51.5 million in Q3 2025.
- A 5-year average of $78.7 million and a median of $82.0 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities soared 44.26% in 2023, then slumped 42.53% in 2025.
- Over 5 years, Total Liabilities stood at $84.0 million in 2022, then rose by 5.8% to $88.9 million in 2023, then slipped by 7.76% to $82.0 million in 2024, then slipped by 29.38% to $57.9 million in 2025, then retreated by 0.24% to $57.7 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $57.7 million, $57.9 million, and $51.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 61.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.78 Mn |
| Mar 31, 2026 | 57.75 Mn |
| Dec 31, 2025 | 57.88 Mn |
| Sep 30, 2025 | 51.51 Mn |
| Jun 30, 2025 | 55.14 Mn |
| Mar 31, 2025 | 64.17 Mn |
| Dec 31, 2024 | 81.96 Mn |
| Sep 30, 2024 | 82.18 Mn |
| Jun 30, 2024 | 95.94 Mn |
| Mar 31, 2024 | 79.31 Mn |
| Dec 31, 2023 | 88.86 Mn |
| Sep 30, 2023 | 101.42 Mn |
| Jun 30, 2023 | 118.39 Mn |
| Mar 31, 2023 | 76.20 Mn |
| Dec 31, 2022 | 83.99 Mn |
| Sep 30, 2022 | 84.14 Mn |
| Jun 30, 2022 | 82.07 Mn |
| Mar 31, 2022 | 77.74 Mn |
| Dec 31, 2021 | 78.99 Mn |
| Sep 30, 2021 | 75.50 Mn |